Workflow
千鼠万抗
icon
Search documents
排队两年 百奥赛图“回A”上会
Bei Jing Shang Bao· 2025-09-23 16:18
Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to undergo its IPO review on September 24, 2025, after a two-year wait on the Sci-Tech Innovation Board, highlighting its progress in the biopharmaceutical sector and its innovative "Thousand Mice Ten Thousand Antibodies" program [1][4]. Group 1: Company Overview - Baiaosaitu was established in 2009 and operates as a preclinical CRO and biotechnology company, providing innovative animal models and drug development services based on its proprietary gene editing technology [1]. - The company has developed the RenMice platform, which allows for large-scale drug discovery targeting nearly a thousand potential drug targets [1]. Group 2: IPO Process and Financial Performance - The company was accepted for its Sci-Tech Innovation Board IPO on June 20, 2023, and has undergone two rounds of inquiries prior to the upcoming review [4]. - Financial data shows that Baiaosaitu's revenue increased from approximately 534 million yuan in 2022 to 980 million yuan in 2024, with a turnaround to a net profit of approximately 33.54 million yuan in 2024 after previous losses [5]. - In the first half of 2023, the company achieved a revenue of 621 million yuan, a 51.27% increase year-on-year, and reported a net profit of approximately 47.99 million yuan, indicating a successful recovery from losses [6]. Group 3: Research and Development Challenges - The company has experienced a significant reduction in its R&D personnel, with the number of dedicated R&D staff dropping from 58 in 2022 to just 5 in 2024, raising concerns about its innovation capacity [7]. - Governance issues are also present, as the major shareholders, who are a married couple, control over 27% of the voting rights, which may impact decision-making processes [7]. Group 4: Fundraising and Strategic Direction - Baiaosaitu has reduced its planned fundraising amount from 1.893 billion yuan to 1.185 billion yuan for its IPO, focusing on early drug development services, antibody drug research, and clinical projects [7][8]. - The company asserts that this reduction in fundraising will not alter its strategic direction, as the core projects will still revolve around its main business and technology platforms [8].
携“千鼠万抗”计划冲刺科创板,百奥赛图“回A”上会迎考
Bei Jing Shang Bao· 2025-09-23 10:17
科创板IPO排队超两年,百奥赛图(北京)医药科技股份有限公司(以下简称"百奥赛图")终于迎来了上会机会,上交所上市审核委员会 定于9月24日召开2025年第38次上市审核委员会审议会议,审议百奥赛图的首发事项。 招股书显示,百奥赛图成立于2009年,是一家临床前CRO以及生物技术企业。公司基于自主开发的基因编辑技术提供各类创新模式动物以 及临床前阶段的医药研发服务,并利用其自主开发的RenMice全人抗体小鼠平台,针对人体内近千个潜在药物靶点进行规模化药物发现与 开发(以下简称"千鼠万抗"),并将有潜力的抗体分子对外转让、授权或合作开发。 百奥赛图方面向北京商报记者表示,"千鼠万抗"计划自2020年启动,已实现阶段性成果。针对千余个靶点形成了近百万个抗体结合表位的 分子序列"货架"。商业化模式包括抗体分子序列授权/转让、合作开发,以及RenMice小鼠对外授权和抗体制备服务,公司可获取首付款、 里程碑付款及销售分成。目前,公司已与德国默克、吉利德、IDEAYA、Neurocrine、翰森制药、华润生物、荣昌生物、ADC Therapeutics 等数十家国内外知名药企达成合作。这表明"千鼠万抗"已成为公司对外 ...